Orion Pharma (DHA:ORIONPHARM) Moat Score: 0/10 (As of Jul. 01, 2026)


DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
69 GF Score
Price BDT28.60
GF Value BDT20.31
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Moat Score?

Orion Pharma has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Orion Pharma has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Orion Pharma might have No Moat - No discernible moat.

Orion Pharma  (DHA:ORIONPHARM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Orion Pharma Moat Score Related Terms

DHA:ORIONPHARM
69GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT28.60 is trading 40.8% above its estimated GF Value™ of BDT20.31. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Moat Score: 0
  • GF Value™: BDT20.31 vs. price of BDT28.60 (40.8% above fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score

Get the complete analysis for DHA:ORIONPHARM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT28.60
Price
BDT20.31
GF Value